![](/img/cover-not-exists.png)
Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study
Paul, Carle, Griffiths, Christopher E.M., van de Kerkhof, Peter C.M., Puig, Lluís, Dutronc, Yves, Henneges, Carsten, Dossenbach, Martin, Hollister, Kristin, Reich, KristianLanguage:
english
Journal:
Journal of the American Academy of Dermatology
DOI:
10.1016/j.jaad.2018.06.039
Date:
June, 2018
File:
PDF, 1.65 MB
english, 2018